Baizhu Chen

Prof. Dr. Baizhu Chen


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2021 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
BCBaizhu Chen
Baizhu Chen
WKWei Kang
Wei Kang
JSJing Sun
Jing Sun
RZRuntao Zhu
Runtao Zhu
YYYue Yu
Yue Yu
ZDZhuojun Dai
Zhuojun Dai

9 February 2024 in Exploration
Verified
Journal Article
Open access
JTJunJie Tang
JunJie Tang
YLYadong Liu
Yadong Liu
YXYifan Xue
Yifan Xue
ZJZhaozhong Jiang
Zhaozhong Jiang
BCBaizhu Chen
Baizhu Chen
JLJie Liu
Jie Liu
Prodrug‐based self‐assembled nanoparticles (PSNs) with tailored responses to tumor microenvironments show a significant promise for chemodynamic therapy (CDT) by generating highly toxic reactive oxygen species (ROS). However, the insufficient level of intracellular ROS and the limited drug accumulation remain major challenges for further clinical transformation. In this study, the PSNs for the delivery of artesunate (ARS) are demonstrated by designing the pH‐responsive ARS‐4‐hydroxybenzoyl hydrazide (HBZ)‐5‐amino levulinic acid (ALA) nanoparticles (AHA NPs) with self‐supplied ROS for excellent chemotherapy and CDT. The PSNs greatly improved the loading capacity of artesunate and the ROS generation from endoperoxide bridge using the electron withdrawing group attached directly to C10 site of artesunate. The ALA and ARS‐HBZ could be released from AHA NPs under the cleavage of hydrazone bonds triggered by the acidic surroundings. Besides, the ALA increased the intracellular level of heme in mitochondria, further promoting the ROS generation and lipid peroxidation with ARS‐HBZ for excellent anti‐tumor effects. Our study improved the chemotherapy of ARS through the chemical modification, pointing out the potential applications in the clinical fields.

19 December 2022 in Journal of Controlled Release
Verified
Journal Article
Closed access
BCBaizhu Chen
Baizhu Chen
XZXiaoge Zhang
Xiaoge Zhang
LCLili Cheng
Lili Cheng
XCXiaomei Chen
Xiaomei Chen
JTJunjie Tang
Junjie Tang
JLJie Liu
Jie Liu

25 October 2022 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
MLMeiting Li
Meiting Li
YZYaqian Zhang
Yaqian Zhang
XZXiaoge Zhang
Xiaoge Zhang
ZLZhuoyin Liu
Zhuoyin Liu
JTJunjie Tang
Junjie Tang
JLJie Liu
Jie Liu

16 November 2021 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
MFMiao Feng
Miao Feng
MLMeiting Li
Meiting Li
RDRui Dai
Rui Dai
SXShuting Xiao
Shuting Xiao
JTJunjie Tang
Junjie Tang
JLJie Liu
Jie Liu
A FeS 2 @SRF@BSA nanoplatform was established for chemo-combined PTT enhanced PDT/CDT to achieve an “all-in-one” therapeutic agent. The designed nanoplatform greatly inhibited the tumor growth and achieved sufficient in vivo antitumor efficacy.

5 March 2018 in Biomacromolecules
Verified
Journal Article
Closed access
BCBaizhu Chen
Baizhu Chen
LYLei Yu
Lei Yu
ZLZhibo Li
Zhibo Li
CWChi Wu
Chi Wu